4th European Biotech & Medtech Investor Day

by France Biotech
THERADIAG SA

NAME OF THE CEO
Michel FINANCE

ADDRESS
14 Rue Ambroise Croizat,
77183 Croissy Beaubourg
(Paris IDF)

EMAIL
info@theradiag.com

www.theradiag.com

MANAGEMENT TEAM
CEO: Michel FINANCE
CFO: Fabienne FRANCOIS

MISSION

On top of developing, manufacturing and commercializing IVD diagnostics, Theradiag innovates and develops theranostics tests that measure the efficiency of biotherapies in the treatment of autoimmune diseases and cancer. Theradiag is actively participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance.

TECHNOLOGY

Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies.

ALLIANCES/PARTNERSHIPS

US: Pfizer, UCB, Luminex Corp, Inform Diagnostics (MIRACA Life Sciences), Janssen,
France/Europe: SEBIA, Biogaran, Pfizer, MSD, Biogen, UCB.

UPCOMING CATALYSTS

Lisa Tracker development in the US market & in the international market.
Discussion & signature of new pharmaceutical agreements in the theranostic field,
Development of a new technology/instrument for Lisa Tracker.

MARKET FIGURES (listed companies)

Revenues 2017: 9,10M€
Date of IPO: December 2012
Ticker: ALTER
Exchange: Euronext Paris
Currency: EUR
Market cap: 14M€
Price: 1,56€
52-weeks-high: 3,30€
52-weeks-low: 1,38€
Average daily volume: 43,565
COMPANY SUMMARY

BIO Boston 1x1 meeting

COMPANY SUMMARY

THERADIAG SA

NAME OF THE CEO
Michel FINANCE

ADRESS
14 Rue Ambroise Croizat, 77183 Croissy Beaubourg (Paris IDF)

EMAIL
info@theradiag.com

www.theradiag.com

MANAGEMENT TEAM
CEO: Michel FINANCE
CFO: Fabienne FRANCOIS

TARGETED MARKET

Theradiag is commercializing its TDM (Therapeutic Drug Monitoring) and IVD products worldwide directly or through partners. More than 50% of sales are done abroad.

LISTED COMPANY

CREATION DATE
29 December 1986

KEY FIGURES

<table>
<thead>
<tr>
<th>€ m</th>
<th>2016</th>
<th>2017</th>
<th>Growth (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>9.0</td>
<td>9.1</td>
<td>+1%</td>
</tr>
<tr>
<td>EBIT</td>
<td>&lt;2.1&gt;</td>
<td>&lt;2.2&gt;</td>
<td>/</td>
</tr>
<tr>
<td>Net Income</td>
<td>&lt;2.1&gt;</td>
<td>&lt;2.2&gt;*</td>
<td>/</td>
</tr>
<tr>
<td>Cash Position</td>
<td>3.7</td>
<td>5.2</td>
<td>+40%</td>
</tr>
</tbody>
</table>

* before exceptional charges

ANALYST COVERAGE

<table>
<thead>
<tr>
<th>Broker</th>
<th>Date</th>
<th>Reco.</th>
<th>Target Price</th>
<th>Potential (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>KEPLER</td>
<td>April 11, 2018</td>
<td>Buy</td>
<td>2.70€</td>
<td>73%</td>
</tr>
<tr>
<td>Portzamparc</td>
<td>April 11, 2018</td>
<td>Buy</td>
<td>2.80€</td>
<td>79%</td>
</tr>
<tr>
<td>Average:</td>
<td>-</td>
<td>-</td>
<td>2.80€</td>
<td>76%</td>
</tr>
</tbody>
</table>

SHAREHOLDERS (percentage)

Management 1.10%
Public investors 90.40%
HOB Biotech Group 8.60%

PIPELINE

<table>
<thead>
<tr>
<th>product</th>
<th>faisability study</th>
<th>assay optimisation</th>
<th>validation study</th>
<th>CE marking</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisa Tracker kits in Ai/Cancer</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Lisa Tracker kits on multiplex</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>new IVD kits in Ai</td>
<td>x</td>
<td>x</td>
<td></td>
<td>x</td>
</tr>
</tbody>
</table>